Clinical experience with routine Gd-DTPA administration for MR imaging of the brain.
A retrospective analysis of intracranial magnetic resonance (MR scans of 514 patients who underwent nonselective Gd-DTPA enhanced MR imaging was performed to determine the efficacy of this protocol for Gd-DTPA administration. This report reviews the frequency and clinical significance of abnormally enhancing areas that were entirely undetectable on precontrast images or would have been missed without the retrospective knowledge of enhancement. Fifty-seven patients (11% of the 514 patients studied) showed enhancing lesions, with 16 (3.1% of the total) of these patients demonstrating one or more lesions identifiable only on postcontrast images. Of those 16 patients, 8 had other focal abnormalities on precontrast studies, whereas the remaining 8 (1.6% of the total) had negative precontrast studies. The new diagnoses affected clinical management directly in five patients and in another nine contributed potentially significant information. Considerations regarding a selective versus nonselective protocol for Gd-DTPA administration for intracranial MR imaging and the use of clinical information to augment these protocols are discussed.
Schwaighofer
B W
BW
Department of Radiology and Magnetic Resonance Institute, University of California, San Diego.
Klein
M V
MV
Wesbey
G
G
Hesselink
J R
JR
D001921:Brain / Q000473:pathology*; D001932:Brain Neoplasms / Q000175:diagnosis*; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid; D012189:Retrospective Studies
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA